VTVT
$36.70
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
Recent News
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the best hot stocks to buy according to analysts. On March 10, vTv Therapeutics reported its financial results for Q4 and the full-year 2025. For 2025, the company reported a net loss of $27.0 million, with R&D expenses rising to $17.9 million due to increased investment in clinical […]
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VTv Therapeutics: Q4 Earnings Snapshot
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 58 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 98 cents per share.
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., transforming a regional agreement into a global collaboration for the development of HPP737. Under the amended terms, Newsoara gains exclusive worldwide rights to develop and commercialize this […]
An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here?
vTv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and inflammatory disorders, all in clinical trials. VTVT has surged 182% over the past year, hitting a two-year high, with strong technical momentum. Wall Street leans “Strong Buy” with targets up to $47, but...